Onyx Pharmaceuticals (ONXX) Q2 2012 Earnings Call August 01, 2012 5:00 pm ET Executives Amy Figueroa N. Anthony Coles - Chief Executive Officer, President and Director Helen Torley - Chief Commercial officer and Executive Vice President Matthew K. Fust - Chief Financial Officer, Principal Accounting Officer and Executive Vice President Barbara Klencke Analysts Michael G. King - Rodman & Renshaw, LLC, Research Division Cory William Kasimov - JP Morgan Chase & Co, Research Division Terence C. Flynn - Goldman Sachs Group Inc., Research Division Rachel L. McMinn - BofA Merrill Lynch, Research Division Howard Liang - Leerink Swann LLC, Research Division Biren Amin - Jefferies & Company, Inc., Research Division Matthew R. Wooten - Robert W. Baird & Co. Incorporated, Research Division Navdeep Singh - Deutsche Bank AG, Research Division Geoffrey C. Porges - Sanford C. Bernstein & Co., LLC., Research Division Ling Wang - Summer Street Research Partners Echo Yinghui He - Maxim Group LLC, Research Division Ryan Martins - Lazard Capital Markets LLC, Research Division Nicholas Bishop - Cowen and Company, LLC, Research Division Ying Huang - Barclays Capital, Research Division Marshall Urist - Morgan Stanley, Research Division Jim Birchenough - BMO Capital Markets U.S. PresentationOperator
Welcome to the Onyx Pharmaceuticals Conference Call. My name is Trish, and I will be your operator for today's call. [Operator Instructions] Please note that this conference is being recorded. I would now like to turn the call over to Onyx Pharmaceuticals. Amy Figueroa Thanks, Trish. Good afternoon. I'm Amy Figueroa, Senior Director of Investor Relations at Onyx Pharmaceuticals. Thank you for participating on our second quarter 2012 financial results conference call.